Tools for Early R&D

Disease Target Assessment

Disease Target Assessment (DTA) estimates an asset’s commercial performance given uncertainty about its clinical attributes. Our DTAs help early development teams understand the peak-year patient share that they can expect their asset to achieve. This output is driven by the clinical benefit offered by the asset vs. the SOC, its relative cost, as well as the competitive environment and epidemiology.